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Abstract: The immune system in the gastrointestinal
tract plays a crucial role in the control of infection, as it
constitutes the first line of defense against mucosal
pathogens. The attractive features of oral immunization
have led to the exploration of a variety of oral delivery
systems. However, none of these oral delivery systems
have been applied to existing commercial vaccines. To
overcome this, a new generation of oral vaccine delivery
systems that target antigens to gut-associated lymphoid
tissue is required. One promising approach is to exploit
the potential of microfold (M) cells by mimicking the entry
of pathogens into these cells. Targeting specific receptors
on the apical surface of M cells might enhance the entry
of antigens, initiating the immune response and conse-
quently leading to protection against mucosal pathogens.
In this article, we briefly review the challenges associated
with current oral vaccine delivery systems and discuss
strategies that might potentially target mouse and human
intestinal M cells.
Advantages and Challenges Surrounding Mucosal
Vaccines
The mucosal immune system is a critical line of defense against
infectious diseases, as the majority of infections are initiated at
mucosal sites [1–3]. Therefore, the induction of specific immune
responses at mucosal sites may be able to control infections at their
point of entry into the body. Over the past few decades, several
candidate vaccines have been designed and tested by various
mucosal routes in pre-clinical or clinical trials. Although the
mucosal immune system comprises several anatomically remote
and functionally distinct compartments, it is firmly established that
the oral ingestion or intranasal administration of antigens induces
humoral and cellular responses not only at the site of antigen
exposure but also in other mucosal compartments [4,5]. This is
due to the dissemination of antigen-sensitized precursor B and T
lymphocytes from the inductive (e.g., intestinal Peyer’s patches) to
the effector sites such as the above mentioned glands. However,
not all inductive sites display comparable ability to induce equal
responses at all effector sites. Despite several advantages, as
compared to systemic injections, the delivery of vaccines by
mucosal routes, particularly through the genitals or rectum, has
not been shown to be very practical in human trials [6–8]. In
addition, it is hard to administer a mucosal vaccine through the
genital tract, as the immunological features of the female
reproductive tract, in particular, alter dramatically in response to
hormonal fluctuations during the menstrual cycle [9–11]. In
addition, both male and female genital tracts lack inductive
mucosal sites analogous to intestinal Peyer’s patches [12].
Furthermore, rectal vaccinations have been shown to induce only
modest and localized immune responses, and are not very effective
in larger animals and humans [13,14]. The pitfalls in quantifying
effector cells in rectal tissues, combined with the intricacies of the
inoculation route, are some other major challenges associated with
rectal immunization. Therefore, in order to advance a mucosal
vaccine for human use, the routes of administration appear to be
limited to oral and nasal administration.
Nasally delivered vaccines are easy to administer and have been
shown to be more promising for inducing both mucosal as well as
systemic immune responses [15–17]. It should be stressed that the
immune system of the upper respiratory tract (nasal cavity,
oropharynx, trachea, and large bronchi) and lower respiratory
tract (bronchioli and alveoli) display marked differences with
respect to the dominance of Ig isotypes and induction of humoral
immune responses. While the induction of dominant IgA
responses in the upper respiratory tract is of importance in the
protection at this locale, the lower respiratory tract is the domain
of antibodies, of the IgG isotype of circulatory origin. Conse-
quently, systemic immunizations with, for example, pneumococcal
polysaccharide vaccines, induce protective immune responses. A
nasal spray influenza vaccine (FluMist) containing live attenuated
influenza has been approved for human use since 2003 [18,19]. In
an HIV study, macaques that were intranasally vaccinated with
SHIV-capturing nanospheres demonstrated elevated levels of IgA
and IgG antibodies [20]. Additionally, these vaccinated macaques
showed a higher frequency of CD4 +T cells and lower viral loads
compared to control macaques after a SHIV challenge. However,
two human clinical trials involving nasal administration of HIV-1-
derived antigens were recently terminated due to safety concerns.
The potential for side effects such as Bell’s palsy and damage to the
olfactory nerves and the nasal epithelium have been cause for
concern; however, these side effects could have occurred due to
the use of highly reactogenic adjuvants and not because of the
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effects, and the reason that the gastrointestinal (GI) tract is the first
line of defense against mucosal pathogens, has led many scientists
to pursue oral vaccination. The advantages and disadvantages of
each route of mucosal immunization are summarized in Table 1.
In this article, the advantages, challenges, and pitfalls with this
route of vaccination are addressed. We also briefly review current
options for oral delivery systems and approaches that have been
explored to improve the uptake of potential vaccines. Oral
vaccines have the ability to induce both mucosal and systemic
immune responses and are safer, easier to administer, and do not
require sterile needles and syringes [24–27]. Therefore, oral
vaccines could more easily meet the needs of affected people in
developing countries, where access to trained medical professionals
is frequently limited. Although oral vaccines have several attractive
features, the limited numbers of approved oral vaccines attest to
the challenges associated with mucosal vaccine design. Studies
involving oral vaccine use have been limited due to several
challenges, such as difficulties in the collection and processing of
external secretions, a lack of standardized assays, the induction of
tolerance, the stability of antigens in the harsh conditions of the GI
tract, and the antigen–microbial interactions that are continuously
occurring in the large intestine [28,29]. It is for these reasons that
only a limited number of oral vaccines are currently licensed,
compared to many parenteral vaccines.
Oral Vaccine Delivery Systems
Recombinant or attenuated strains of various bacteria such as
Salmonella, Escherichia coli, Listeria, Shigella, and Lactobacilli have been
used as a vectors to deliver antigens into the gut-associated
lymphoid tissue (GALT) [30–35]. While some interesting results
have been reported for these oral delivery systems, immune
responses against the vectors eventually predominated over time
[36,37]. In addition, glycosylated antigens cannot be produced in
bacteria [38]. Furthermore, over 10
14 microorganisms of .20,000
species reside in the large intestine [43]. Such a large competing
population would greatly diminish the chances of colonization and
subsequent induction of a vigorous immune response through such
vector microorganisms. Oral delivery of live attenuated recombi-
nant viruses such as adenoviruses (Ad), poxviruses, influenza,
herpes viruses, and polioviruses encoding specific antigens has
been also tested in several oral vaccine studies. While these viral
vectors showed promising results, pre-existing immunity to these
viruses may prevent their ability to deliver desired antigens.
Oral delivery of DNA vaccines encoding various antigens has
also been evaluated in various animal studies [1,2,39–41]. DNA
vaccines contain unmethylated CpG motifs with binding activity
to TLR9 receptors. This characteristic assists in activating a
variety of cells including dendritic cells (DCs), macrophages,
monocytes, and splenocytes [42]. The TLR9 signaling pathway
leads to IL-1b and INF-c secretion, polarizing the immune
response to a Th1 type. One of the pitfalls associated with DNA
vaccines is the low uptake of DNA from the intestinal tract, which
consequently limits B and T cell immune responses [43].
Over the past few years, specific T and B cell epitopes have been
characterized in tumor and viral antigens. Synthesis of peptide
epitopes for use as a vaccine requires an understanding of T and B
cell immunodominant epitopes in the protein structure, and their
interaction with major histocompatibility complexes (MHCs) or
human leukocyte antigen (HLA) complexes [44–48]. The design
and development of immunodominant multivalent epitopes
representing diverse HLA types is an attractive strategy against
hypervariable viruses such as HIV-1 and hepatitis C virus (HCV).
One of the pitfalls with this approach is that peptide vaccines are
not immunogenic alone, and thus require carriers and potent
adjuvants to enhance their immunogenicity. The use of lipidated
peptide immunogens is one of several strategies currently being
pursued for the improvement of peptide immunogenicity [49–51].
Previous studies have demonstrated that the presence of lipid
moieties on peptides prolongs the duration of antigen presentation,
enhances cytosolic uptake of peptide immunogens, activates innate
immunity due to a TLR2 agonist effect, and differentiates non-
activated B cells into immunoglobulin-secreting plasma cells [52–
55]. Although no commercialized peptide vaccine is yet available,
this approach has shown promising results in animal studies [56].
Oral delivery of peptide vaccines has been evaluated in pre-clinical
and clinical trials. In a phase I study, 33 HIV-seronegative
volunteers were primed orally three times with a V3 peptide
derived from HIV-1 isolate MN, followed by a systemic boosting
[57]. While no broad humoral or cellular immune responses were
Table 1. Advantages and Disadvantages of Each Route of Mucosal Immunization Is Summarized.
Route of Immunization Advantages Disadvantages
Genital delivery Specific systemic and mucosal IgG and IgA antibody
responses in genital secretions
Administration of antigens via male genital tract is impractical;
immunological properties of the female reproductive tract alter during
the menstrual cycle
Rectal delivery Specific antibodies and cytotoxic T lymphocyte response in
mucosal secretion of small animals
Modest levels of local IgG and IgA titers in human; difficulty in
quantifying effector cells in rectal tissues; difficulty in the route of
inoculation
Nasal delivery Enhances both humoral and cellular immune responses in
systemic and mucosal sites; easy to administer, no needles
or syringes are needed
Lack of strong adjuvants; side effects such as Bell’s palsy and damage to
olfactory nerves and the nasal epithelium
Inhalation delivery Enhances both humoral and cellular immune responses in
systemic and mucosal sites; administered in both dry
powder or liquid formulations
A device is required; risk of exacerbation of respiratory infections;
difficulty in administration to infants or congested patients; dose
delivery issues
Sublingual delivery Antigens are absorbed quickly; induction of IgG in systemic
sites; no needles or syringes are needed
Dose delivery issues; difficulty in formulation of antigens; lack of strong
adjuvants
Oral delivery Enhances immune responses in systemic and mucosal sites;
safe; easy to administer; no health care professional is
needed; easy to scale up
Induction of tolerance in some animals; requires large dose of antigens;
lack of stability of antigens against the harsh conditions of the GI
doi:10.1371/journal.ppat.1001147.t001
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ment of orally administered peptide vaccines.
Plant-based oral vaccines are another delivery system that has
been tested in recent years [58–61]. Seed crops such as rice, maize,
and soybean appear to be suitable expression and delivery systems
that offer several advantages, such as resistance to intestinal
enzymes,rapidscale-upofexogenousantigens,low-costproduction,
and a decreasedriskofcontaminationbyhuman pathogens [62,63].
In a mouse study, MucoRice-expressed cholera toxin subunit B
(CTB) was administered orally to animals, and specific immune
responses and neutralizing activity in both systemic and mucosal
compartments were detected [64]. Interestingly, immunized
animals with MucoRice-CTB demonstrated protection from an
oral challenge with cholera toxin compared to control animals. In a
similar study conducted in a non-human primate model, cynomol-
gus macaques received orally administered MucoRice-CTB.
Animals were found to have CT-specific, neutralizing antibodies,
and high levels of systemic IgG and intestinal IgA antibodies [65].
Over the past few years, several oral vaccine delivery vehicles
such as liposomes, dendrimers, multiple emulsions, immune
stimulating complexes (ISCOMs), biodegradable polymers such
as poly (lactide-co-glycolide acid), and dendrimers have also been
identified [66–70]. Antigens, adjuvants, and targeting molecules
could be incorporated individually or in combination into these
microparticles. These vehicles may thus act as immunostimulants
while preventing the degradation of immunogens by enzymes in
the GI tract. These particulate formulations might also interact
with microfold (M) cells and release immunogens slowly,
consequently promoting phagocytosis. Some microparticle studies
have shown that the addition of polymers such as chitosan might
increase the interaction of antigens with the intestinal mucosal
surface [66,67]. The efficacy of these microparticles has been
tested in several animal studies and in a limited number of clinical
trials. In a human trial, five volunteers were orally immunized with
a surface Enterotoxigenic Escherichia coli (ETEC) polymeric protein
(CS6) associated with a biodegradable polymer, poly-lactide-co-
glycolide (PLG) [68]. Oral administration of these microparticles
was safe, and four out of five volunteers showed IgA responses and
a 3.5-fold increase in the levels of serum IgG antibody responses.
In a study by Frey et al. [69], oral administration of CTB was
tested as a model for enhancing antigen uptake by intestinal
epithelial cells. CTB was chosen as it promotes immune responses
when co-administered orally, and its receptor (ganglioside GM1) is
present on all intestinal epithelial cell surfaces. In vivo results in
rabbits showed that soluble CTB-FITC (diameter of 6.4 nm) was
able to bind to apical membranes of both enterocytes and M cells.
Whereas CTB coupled to colloidal gold (diameter of 28.8 nm)
bound only to M cells and not enterocytes, CTB-coated micro-
particles (diameter of 1.13 mm) failed to bind to either rabbit
enterocytes or rabbit M cells. In a study by Mann et al. [70], two
different sizes of a liposome-entrapped influenza antigen were
delivered orally in a mouse model. The group of mice that was
orally immunized with larger liposomes (60–350 nm and 400–
2,500 nm) showed a greater Th1 bias, serum IgG2a production,
and antigen-induced splenocyte IFN-c production, compared to
mice having received liposomes 10–100 nm in size. While this
study also showed that microparticle size is an important factor
associated with particle uptake, the size of the microparticles was
quite different from a previous study.
However, sizing is not the only issue with these microparticles.
A variety of additional parameters, including the ratio and
quantity of chemical components, the amount of encapsulated
antigen, hydrophobicity, the ionic surface charge, the type of
associated adjuvants, and the dose of administration are also
crucial, and should be optimized. In this context, the association of
M cell–targeting ligands on the surface of the delivery vehicles
might also enhance the binding specificity to intestinal Peyer’s
patches. In the next section, we briefly describe the M cell surface
markers that could be considered in a strategy to enhance capture
and uptake of orally administered vaccines.
Targeting the Apical Surface of M Cells
M cells are specialized epithelial cells that predominantly reside
in the follicle-associated epithelium (FAE) overlying Peyer’s
patches. M cells also reside in other sections of the intestinal tract
such as the colon and rectum [71–74]. M cells are identifiable by
their flattened apical surfaces, fewer numbers of cytoplasmic
lysosomes, greater numbers of mitochondria, and the absence of
glycocalyx covering their surfaces. It also appears that mouse M
cells express particular surface markers, compared to enterocytes,
such as b1 integrin or a-L-fucose-specific (L-fucose) lectin [75]. In
contrast to enterocytes, M cells take up antigens or microorgan-
isms from the intestinal lumen (Figure 1) by phago-, endo-, or
pinocytosis and transcytosis, and deliver them to the underlying
immune system of the mucosae. This phenomenon also occurs by
other mechanisms, for instance in intestinal DCs; however, this
will not be discussed here. M cells are not limited to the GALTs,
and are also present in other mucosal tissues such as nasopharyn-
geal-associated lymphoid tissue (NALT) and bronchus-associated
lymphoid tissues (BALT) and tonsils [76,77]. It has been shown
that M cells in NALT are a major site of virus entry as well as
vaccine delivery; however, limited studies have been reported with
regards to the roles of NALT and BALT in the uptake and
transport of vaccine-delivered antigens.
The ability of M cells in Peyer’s patches to take up and
transcytose diverse numbers of microorganisms to antigen-present-
ing cells (APCs) have made M cells an ideal target for vaccine
delivery to the mucosal immune system [78–80]. It is estimated that
only 1 out of 10 million epithelial cells in the intestinal tract is an M
cell (approximately 5% in humans and 10% in mice) [81]. Due to
these low numbers of M cells, several approaches have been
attempted to enhance M cell targeting. It has been indicated that M
cell numbers in Peyer’s patches are increased after exposure to
Streptococcus pneumonia R36a [82]. However, these increased numbers
of M cells may uptake all antigens in the intestinal epithelium and
not just the antigens of interest, consequently increasing the
probability of inducing food allergies and inflammatory diseases.
Therefore, it might be more reasonable to target the existing M cells
in Peyer’s patches than to try to amplify their numbers.
Targeting specific receptors on the apical surface of M cells may
have the ability to specifically increase the uptake and presentation
of antigens, consequently initiating the immune response and
inducing protection against infectious challenge. To date, only
limited numbers of M cell receptors and their ligands have been
identified, and most of these receptors are not only expressed in M
cells but in neighboring enterocytes as well. Some important
pathogen recognition receptors (PRRs), such as toll-like receptor-4
(TLR-4), platelet-activating factor receptor (PAFR), and a5b1
integrin, are expressed on the surface of human and mouse M cells
[83–85]. These innate immune system molecules interact with
pathogen-associated molecular patterns (PAMPs) such as lipopoly-
saccharide, lipotechoic acid, peptidoglycan, and bacterial flagellin.
This interaction is crucial for the translocation of bacteria across
the lumen. Consequently, targeting PRRs might be a suitable
strategy for enhancing the uptake of orally administered vaccines
by M cells. This interaction activates several signaling pathways
that may play important roles in M cell functions. For instance, M
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Yersinia spp., via the a5b1 integrin, and inhibition of this adhesion
molecule significantly inhibits transcytosis of M cells [86–88].
While PRRs are also expressed on neighboring enterocytes (a
challenge in targeting only M cells), the expression patterns of
these receptors are varied. For instance, a5b1 integrin is dispersed
on the lateral and basolateral surfaces of enterocytes, while in M
cells, a5b1 is distributed only on the apical surface.
Lectin-binding studies in experimental animals have shown that
M cells express on their surface a particular glycosylation pattern
[89,90]. Several studies showed that Ulex europaeus agglutinin-1
(UEA-1), a lectin specific for a-l-fucose residues, selectively binds to
M cells in murine Peyer’s patches [91–94]. In a study by Manocha
et al. [94], the UEA-1 coated on the surface of microparticles
encoding HIV genes had the capability to bind to the apical surface
of M cells. In another study, by Chionh et al. [95], oral vaccination
in a mouse model with killed whole Helicobacter pylori and UEA-1 or
Campylobacter jejuni and UEA-1 induced protective responses against
live challenge. However, M cell glycosylation patterns are not
common to all species, and it remains to be seen whether it can be
used to effectively target human M cells [96]. Human M cells have
proven to be largely anonymous, as it has been difficult to isolate
enough of such cells for further characterization and functional
evaluation. Therefore,the specificreceptorrequirementsforhuman
M cells and how to specifically target these receptors remains a
challenge. In recent years, a few in vitro human M cell models have
been established [97,98]. One of the most common M cell–like
models is comprised of co-cultures of human colon carcinoma cells
(Caco-2) along with human lymphoblastoid B cell lines (Raji B cells)
[99,100]. This in vitro model has been used to study the
morphology and expression of M cell surface markers and antigen
absorption, and to screen oral drug/vaccine delivery systems, as it
closely imitates human M cells. While these M cell–like models have
been used to attempt to further understand human M cells, one of
the concerns of this model pertains to its over-simplification of in
vivo events, as well as the lack of signaling factors from other
immune cells such as T cells that are required for the formation and
optimal function of M cells.
Microarray and three-dimensional imaging of specific molecules
associated with M cells has revealed that a surface marker called
glycoprotein2(GP2)isexpressedonbothhumanandmouseMcells
[101,102]. It appears that GP2 plays an important role in molecular
mechanisms responsible for antigen uptake by M cells. GP2 serves
as a transcytotic apical receptor on the surface of M cells that
specifically binds to type I pili on bacterial outer membranes (FimH)
[101]. Elimination of GP2 reduced the entry and uptake of bacteria
into Peyer’s patches and decreased T cell proliferative and antibody
responses. Altogether, these results suggest that the GP2 protein
might be a promising vaccine target for immunizing against
infectiousdiseases.Severalstudieshave shownthat FimHadhesion–
based vaccines are able to prevent infection by impeding
colonization, enhancing humoral immune responses, and blocking
bacterial attachment [103–105]. It would be excitingto determine if
FimH could direct other antigens to M cells as well.
Figure 1. Schematic diagram of intestinal epithelium showing M cells, Peyer’s patches, intestinal epithelial cells, and pathway of Ag
transport. DC, dendritic cells; IEC, intestinal epithelial cell (NU, nucleus); MC, M cell; IEL, intra epithelial lymphocytes; PP, Peyer’s patches; MW,
macrophages; Pv, particulate Ag in pinocytic vesicle of M cell.
doi:10.1371/journal.ppat.1001147.g001
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were biopsied from volunteers with blood groups type O (two
individuals) and type A (one individual). The binding and cellular
localizations of 31 lectins and ten anticarbohydrate monoclonal
antibodies from biopsy samples were performed by histochemistry
and compared to the nearby enterocytes on Peyer’s patches. Lectin
and antibody results revealed a higher expression of carbohydrates
on enterocytes than M cells. Some lectins and antibodies such as
OPA and anti-Lewis A also reacted with both M cells and
enterocytes. Interestingly, only one (anti-sialyl Lewis A) out of the 41
tested lectins or antibodies largely reacted with human M cells
(,80%) and bound only weakly to the FAE enterocytes (,20%).
While a larger number of human tissue specimens are required to
confirm this oligosaccharide repertoire, an anti-sialyl Lewis A–
mediated vaccine delivery system might be appropriate approach to
enable M cell–targeted mucosal vaccines in humans.
In a study by Misumi et al. [107], the capability of tetragalloyl-D-
lysine dendrimer (TGDK) to target M cells was examined in an in
vitro human M–like cell culture and a rhesus macaque animal
model. The results indicated that TGDK specifically bound to a
human intestinal M–cell like model under in vitro conditions and
was delivered from the M cell surface to the basolateral area. To
examine the in vivo effect of TGDK on M cell targeting, rhesus
macaques were orally administered with enteric coated capsules
containing TGDK-conjugated multiantigens at weeks 0, 2, and 6.
ELISA from feces samples of immunized macaques indicated a high
level of IgA antibody responses. Conversely, the control macaques
did not induce specific IgA in fecal samples. Furthermore, the
immunized macaques with TGDK-conjugated multiantigens also
showed neutralizing activity against SIV infection. These results
concluded that TGDK transports from the lumen into intestinal M
cells,andcanconsequentlybe considered foruseinmucosalvaccine
delivery in humans and non-human primates.
MucosalImmune Responses and MucosalTolerance
Repeated oral administration of large doses of antigen in animal
models result in decreased or abrogated T cell–mediated responses
to a subsequent systemic immunization with the same antigen
[108]. This phenomenon prompts a question concerning the
possible induction of mucosal tolerance by mucosally delivered
vaccines. Importantly, for vaccine efficacy the dominant target of
oral tolerance is the T and not the B cell compartment. As a
matter of fact, initial mucosal administration of antigens by the
oral or nasal routes primes for B cell responses in parallel with
diminished T cell responses in humans as well as in animals [109].
Thus, vaccines whose protective effect is dependent on the
induction of antibodies (which is the target of all currently used
vaccines in humans) are not likely to diminish their efficacy by
mucosal administration of antigens. Furthermore, pre-existing
immune responses induced by systemic immunization cannot be
attenuated or suppressed by subsequent mucosal administration of
the same antigen [109]. However, initial mucosal immunization of
immunologically naı ¨ve subjects (e.g., with HIV-1 vaccines) might
have the undesirable effect of diminishing cell-mediated responses,
including cytotoxic T cell–dependent immunity. Thus, the
temporal sequence of immunization with initial systemic priming
and mucosal boosting as well as the use of certain adjuvants is
likely to prevent the induction of mucosal tolerance.
Concluding Remarks
Over the past few decades, oral immunization has been
extensively studied due to its many attractive features. The
immunological potential, absorption, or limitation in the uptake of
antigens, as well as the characteristic distribution of functional cell
types in the GI tract, have made it a vital target in the
development of oral vaccines. The phenomenon of tolerance is a
crucial challenge to overcome in the development of effective oral
vaccines. Experimental animal studies have indicated that oral
administration of antigens targets the systemic T cell compart-
ment, diminishes cell-mediated immune responses, and induces
tolerance. This phenomenon might lead to the induction of
cytokines such as TGF-b and IL-10, and consequently enhance
antigen-specific antibody responses such as IgA and IgG. While
the humoral immune response is critical in the control of some
mucosal pathogens, its effect might be questionable on other
mucosal pathogens such as HIV and HCV where cell-mediated
immune responses may play a larger role. Opponents to this
tolerance hypothesis, including the authors of this article, believe
that tolerance is not an issue in humans, as it occurs through a
completely different mechanism. Furthermore, some clinical
studies have showed that a combination of oral priming and
systemic boosting might activate both humoral and cellular arms
of the immune system. On the other hand, we think that the
absence of a potent oral vaccine might be due to other challenges,
including antigen degradation by proteolytic enzymes, the low
dose of antigen absorbed, a lack of potent mucosal adjuvants, and
not actively directing antigens to M cells. To overcome these
issues, further work regarding oral vehicle delivery systems that
protect antigens and specifically target M cells is required.
Targeting M cells by mimicking the entry of mucosal pathogens
such as E. coli, Salmonella, and Yersinia may reflect the in vivo
binding specificity required by orally administered antigens.
Regarding this aspect, a number of studies showed that these
pathogens bind to specific lectins expressed on the apical surface of
M cells. The binding of orally administered vaccines to M cell
lectins was further studied in murine models and indicated that a-
L-fucose-lectin (UEA-1) is able to bind specifically to M cells and,
to a lesser degree, enterocytes. However, the characterization of
murine M cells by this lectin-binding pattern did not reflect the
glycosylation patterns present on human M cells. Unfortunately,
human M cell features, function, and differentiation from
neighboring enterocytes are not well understood.
Based on previous studies, by using tetragalloyl-D-lysine
dendrimers, a monoclonal antibody targeting GP2, or using a
monoclonal antibody targeting sialyl Lewis A, it might be possible
to more specifically direct oral delivery systems to human M cells.
However, as these molecules are also expressed on neighboring
enterocytes (albeit at lower levels), it will likely be difficult to devise
an ideal oral delivery system for targeting human M cells. The
understanding of human M cell function, identification of more
specific apical surface molecules, and the improvement of
intestinal M cell–like models are crucial for the design and further
development of M cell–targeted vaccines.
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